Our research and funding documents contain support and reference information for applicants applying for funding, as well as background information for referees and committee members.
This example Memorandum of Understanding (MoU) formalises the intention of the parties to collaborate in a research project and to enter into a sub-contract.
The HRC is responsible to the Minister of Health, and its major funding agreement is through the Minister of Science and Innovation. Our statutory functions are outlined in the Health Research Council Act 1990.
This CV template, used by several other organisations, can be used in all HRC funding applications. It standardises the type of information asked for and eliminates the need for researchers to reformat their CV each time they apply for funding.
This slideshow helps applicants and reviewers interpret the HRC’s Research Impact assessment criterion, which has been further revised for our 2020 funding rounds.
These Guidelines are based on six principles which are mostly taken from the Guidelines of the Royal College of Paediatrics and Child Health 1999 and the European Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine 1996.
These guidance notes are provided to assist health researchers and ethics committees, but they should not be relied upon as a substitute for the provisions of the Health Information Privacy Code 1994 (HIPC).
Beyond the Health Research Council’s committees, there are other important committees and regulatory bodies in New Zealand that contribute to the regulatory environment of health and disability research.
There are guidelines and codes governing use of body parts and tissues that differ in the case of living persons and deceased persons, and depending on what the human materials will be used for.
The Health Research Council's Standing Committee on Therapeutic Trials (SCOTT) undertakes scientific assessment of applications to conduct trials and makes recommendations to the Director-General of Health on whether or not trials should be approved.
